News & Views Newsletters Contact Become a Research Patient

Clinical Trial

A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of SPR001 (Tildacerfont) in Reducing Supraphysiologic Glucocorticoid Use in Adult Subjects with Classic Congenital Adrenal Hyperplasia

Study Status:

Open for enrollment

Contact Information:

(956) 362-2396

Please contact us for more information or to learn if you are eligible to participate.

Study Purpose:

To evaluate the effect of tildacerfont in reducing GC use in subjects with CAH.

Information:

Principal Investigator	Surya N. Mulukutla, MD
Co-PI	Luis Cantu Jr.
Sponsor	Spruce Biosciences
Type of Trial	Interventional

Contact Us For More Info Or To Apply

5323 S. McColl Rd., Edinburg, TX 78539

[email protected]

(956) 362-2390

Useful Links

For Research Participants

About Us

News & Views

© 2023 DHR Health Institute for Research & Development | All Rights Reserved | Terms & Conditions | Site By: KangoMedia